Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 820

1.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
2.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S.

J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015. Epub 2011 Nov 4.

PMID:
22085813
3.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

Blank PR, Szucs TD.

Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028. Epub 2012 Apr 20.

4.

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D.

BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.

5.

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC.

Vaccine. 2010 Nov 10;28(48):7634-43. doi: 10.1016/j.vaccine.2010.09.049. Epub 2010 Sep 28.

PMID:
20883739
6.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
7.

Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Kuhlmann A, von der Schulenburg JG.

Eur J Health Econ. 2017 Apr;18(3):273-292. doi: 10.1007/s10198-016-0770-9. Epub 2016 Feb 23.

PMID:
26905404
8.

Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.

Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ.

Vaccine. 2015 May 7;33 Suppl 1:A154-66. doi: 10.1016/j.vaccine.2014.12.039.

PMID:
25919156
9.

Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.

Stoecker C, Hampton LM, Link-Gelles R, Messonnier ML, Zhou F, Moore MR.

Pediatrics. 2013 Aug;132(2):e324-32. doi: 10.1542/peds.2012-3350. Epub 2013 Jul 1.

10.

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.

Silfverdal SA, Berg S, Hemlin C, Jokinen I.

Vaccine. 2009 Mar 4;27(10):1601-8. doi: 10.1016/j.vaccine.2008.12.033. Epub 2009 Jan 13.

PMID:
19146905
11.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
12.

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.

Vaccine. 2011 Nov 3;29(47):8564-74. doi: 10.1016/j.vaccine.2011.09.025. Epub 2011 Sep 21.

PMID:
21945264
13.

Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.

Wu DB, Roberts C, Lee VW, Hong LW, Tan KK, Mak V, Lee KK.

Hum Vaccin Immunother. 2016;12(2):403-16. doi: 10.1080/21645515.2015.1067351.

14.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
15.

Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.

Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R.

Pediatr Infect Dis J. 2009 Apr;28(4):277-82. doi: 10.1097/INF.0b013e31818e0e2e.

PMID:
19258924
16.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
17.

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

Cho BH, Stoecker C, Link-Gelles R, Moore MR.

Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.

PMID:
24148572
18.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
19.

Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.

Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Jáuregui B, Janusz CB, Clark AD, Castellanos RM.

Vaccine. 2015 May 7;33 Suppl 1:A143-53. doi: 10.1016/j.vaccine.2014.12.078.

PMID:
25919155
20.

Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; Danish Pneumococcal Surveillance Collaborating Group.

PLoS One. 2013;8(1):e51460. doi: 10.1371/journal.pone.0051460. Epub 2013 Jan 24.

Supplemental Content

Support Center